알렉터(ALEC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.84 (-0.54%), 시가총액 $0.24B, 52주 최저~최고 $1.14 ~ $3.32.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Al
알렉터의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
알렉터의 현재 주가는 $1.84 (-0.54%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
알렉터의 시가총액은 약 $0.24B입니다.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational